Navigation Links
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
Date:6/30/2009

Results Demonstrate Positive Proof of Mechanism

SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor.

The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211. The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species. While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.

"The AM211 clinical PD data confirms what we previously observed in pre-clinical models," said Isabelle DeArmond, M.D., Vice President, Clinical Development. "While a great deal of clinical work remains on this program, we are particularly excited since we believe DP2 antagonism would be a novel therapeutic approach to various respiratory diseases."

Bob Baltera, Chief Executive Officer, added, "Once again the Amira team demonstrates our ability to quickly, efficiently and accurately translate scientific efforts into meaningful therapeutic candidates. The fact that we now have clinical data only 25 months after we initiated scientific efforts on this target in our laboratories is a source of pride for the entire Amira team."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardi
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
2. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
3. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
4. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
5. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
6. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
7. Amira Pharmaceuticals Appoints First Vice President of Development
8. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
9. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
10. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
11. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... be a new salve to dominate medicine cabinets of the ... Salamanders may not be the cuddliest of animals, but they ... damaged body parts. Now, a new report published in the ... , identifies a small protein (called a "peptide") from the ... the secret of this amazing wound healing trick in humans. ...
(Date:9/2/2014)... Society of Nuclear Medicine and Molecular Imaging (SNMMI) is ... Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by ... late Kanji Torizuka, MD, PhD, is designed to provide ... medicine and molecular imaging for Japanese physicians in the ... is proud to sponsor the Wagner-Torizuka Fellowship. This program ...
(Date:9/2/2014)... new guideline, the Society for Maternal-Fetal Medicine has recommended ... , "There is no evidence that bed rest ... Center for Maternal and Fetal Medicine and one of ... that bed rest can be harmful for moms, babies, ... are placed on bed rest during their pregnancy. Surveys ...
(Date:9/2/2014)... Vertebral invasive compression fractures called spine ... in our spine suffers crack or gets deformed. Vertebral ... people with osteoporosis or low bone density. Though osteoporosis ... of metastatic tumors and extensive trauma such as an ... also lead to such fractures. , The placement of ...
(Date:9/2/2014)... Sept. 2, 2014 Cancer screening is a critical ... are often more treatable. But while there are already ... there is a great need for even more safe, ... , Now a team of researchers led by Shaoxin ... the potential of a new, non-invasive method to screen ...
Breaking Medicine News(10 mins):Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2Health News:SMFM releases paper on activity restriction in pregnancy 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 3Health News:New method for non-invasive prostate cancer screening 2
... Investigacin Oncolgica (GENYO) of which the University of Granada, ... identified the genetic and phenotypic changes that cause tumor ... the main cause of cancer death- is caused by ... relationship with the organ originally affected. For this to ...
... the University of Michigan Health System shows the risk ... following the implementation of Model of End Stage Liver ... how liver transplant allocation is decided. The study, ... in the Department of Internal Medicine, examined the effect ...
... developing disorders like addiction and depression, according to a ... Proceedings of the National Academy of Sciences . ... coauthor of the paper and a professor of neuroscience ... Sciences. She and coauthor David Sturman, a MD/PhD student ...
... Calif. Researchers at the Stanford University School of Medicine ... effectively predict how deadly a cancer will be. The discovery, ... faster, less expensive and more accurate analysis of cancer risk ... published online Jan. 16 in the Proceedings of the ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... to help most patients suffering from chronic obstructive pulmonary disease ... Emphysema and chronic bronchitis are the two main forms of ... hard for people to breathe. Since most COPD patients ...
... Mozes HealthDay Reporter , MONDAY, Jan. 16 (HealthDay ... significantly more likely to develop acne than their normal-weight peers, ... weight, and more specifically body mass index (BMI, a ratio ... of the common skin condition among teens. Teens, responses ...
Cached Medicine News:Health News:University of Granada researchers identify changes in tumor cells that lead to metastasis 2Health News:U-M News: Kidney failure risk higher for liver transplant patients following policy change 2Health News:Adolescents' brains respond differently than adults' when anticipating rewards 2Health News:Stanford computer algorithm used to identify bladder cancer marker 2Health News:Stanford computer algorithm used to identify bladder cancer marker 3Health News:Vitamin D Won't Help Most COPD Patients: Study 2Health News:Vitamin D Won't Help Most COPD Patients: Study 3Health News:Overweight Teen Girls May Have Higher Acne Risk 2Health News:Overweight Teen Girls May Have Higher Acne Risk 3
(Date:9/2/2014)... Mast Therapeutics, Inc . (NYSE MKT: MSTX) today announced that the ... at the Rodman and Renshaw 16 th Annual Global Investment ... in the Holmes II Salon at The New York Palace Hotel ... parties can access a live audio webcast and slide presentation on ... presentation will be available on the web site for 30 days. ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced that the U.S. Food and ... designation to the investigation of motolimod (VTX-2337) ... doxorubicin (PLD) for the treatment of women ...
(Date:9/2/2014)... , September 2, 2014 , ... EMITF ) announced today following the Company,s ... Ltd. ("Elbit Medical") (TASE: EMTC-M), a subsidiary of the ... fully diluted basis, announced that on September 1, 2014 ... 30.8% of the voting power ("Gamida Cell") and vast ...
Breaking Medicine Technology:Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
... Mumps IgM Enzyme-Linked Immunosorbent Assay ... qualitative detection of IgM antibody ... for the determination of immunological ... this kit have not been ...
... INC. (DAI) Mumps IgG Enzyme-Linked ... for the detection and quantitative ... Mumps virus in human sera. ... used for the determination of ...
... treatment of diseases of the thoracic aorta ... incision in the chest to place a ... This method can result in long hospital ... community is seeking less invasive alternatives to ...
Medicine Products: